Abstracts tagged "COVID-19"

Abstract Number: 1379 • ACR Convergence 2020
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Robyn Domsic¹, Lorinda Chung², Jerry Molitor³, Robert Spiera⁴, Bradley Bloom⁵, Barbara White⁶ and Quinn Dinh⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ³University of Minnesota, Minneapolis, MN, ⁴Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁵Corbus Pharmaceuticals Inc, Norwood, MA, ⁶Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…
Abstract Number: 1884 • ACR Convergence 2020
Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic
Jean Liew¹, Maria Castillo², Ethan Zaccagnino², Patricia Katz³, Nigil Haroon⁴ and Lianne Gensler⁵, ¹University of Washington, Seattle, WA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, Novato, CA, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Response to the global coronavirus disease (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to how people go about their daily lives.…
Abstract Number: 0020 • ACR Convergence 2020
Characteristics of Rheumatology Outpatients with Suspected or Confirmed COVID-19 During the Pandemic in New York City
Medha Barbhaiya¹, Gregory Vitone², Marianna Frey³, Deanna Jannat-Khah⁴, Candace Feldman⁵, Lindsay Lally³, Anne Bass⁶, Jane Salmon³, Mary Crow³, Michael Lockshin¹, Vivian Bykerk³ and Lisa Mandl³, ¹Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York City, NY, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: The incidence and disease severity of COVID-19 in rheumatic disease patients, who may be at higher risk due to underlying immune dysregulation and use…
Abstract Number: 0458 • ACR Convergence 2020
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
Bibi Ayesha¹, Anand Kumthekar¹, Ruchi Jain², Sneha Patel³, Manish Ramesh¹, Denisa Ferastraoaru⁴, Golda Hudes⁴, Merhunisa Karagic⁴, Sheema Zafar¹, Rachel Bartash⁴, Natalia Vasquez-Canizares⁵, Elizabeth Kitsis⁶, Clement Tagoe⁷, Dawn Wahezi⁵, Tamar Rubinstein⁸ and Anna Broder³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Irvington, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Fresh Meadows, NY, ⁸Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Coronavirus disease (COVID-19) infected patients present with a state of ongoing inflammation and an exaggerated inflammatory state due to unregulated cytokine release called the…
Abstract Number: 0605 • ACR Convergence 2020
How Did SARS-CoV2/COVID-19 Pandemic Affected Rheumatology Practice in Latin America? A Regional Survey from PANLAR
Daniel Fernández-Ávila¹, Julián Barahona-Correa¹, Diana Romero-Alvernia¹, Sergio Kowalski², Ana María Sapag Durán³, Antonio Cachafeiro Vilar⁴, Belia Lucía Meléndez Muñoz⁵, Carlos Santiago Pastelín⁶, Daniel Palleiro Rivero⁷, Dina María Arrieta⁸, Guillermo Pons-Estel⁹, Jossiell Then Báez¹⁰, Manuel Ugarte-Gil¹¹, Mario Cardiel¹², Nelly Colman¹³, Nilmo Chávez Pérez¹⁴, Paula Burgos¹⁵, Rubén Montufar¹⁶, Sayonara Sandino¹⁷, Yurilis Fuentes-Silva¹⁸ and Enrique Soriano¹⁹, ¹Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogota, Colombia, ²Unidad de Investigación PANLAR. Universidade Federal do Paraná, Paraná, Brazil, ³Hospital Universitario Japonés, Santa Cruz, Bolivia, ⁴Pacífica Salud - Hospital Punta Pacífica,, Ciudad de Panamá, Panama, ⁵Hospital de la Policía Nacional N1 Quito, Quito, Ecuador, ⁶Instituto Hondureño de la Seguridad Social, Tegucigalpa, Honduras, ⁷Instituto Nacional de Reumatología del Uruguay - Universidad de la República, Montevideo, Uruguay, ⁸Hospital México, San José de Costa Rica, Costa Rica, ⁹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁰Hospital Metropolitano de Santiago (HOMS), Santiago, Dominican Republic, ¹¹Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen and Universidad Científica del Sur, Lima, Peru, ¹²Centro de Investigación Clínica de Morelia, Morelia, Mexico, ¹³Hospital de Clínicas - Universidad Nacional de Asunción, Asunción, Paraguay, ¹⁴Instituto Guatemalteco de Seguridad Social, Ciudad de Guatemala, Guatemala, ¹⁵Universidad Católica de Chile, Santiago de Chile, Chile, ¹⁶Consultorio de Especialidades del Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador, ¹⁷Policlínica Nicaragüense, Managua, Nicaragua, ¹⁸Centro Clínico Universitario de Oriente - Universidad de Oriente, Ciudad Bolivar, Venezuela, ¹⁹Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina
Background/Purpose: Since December 2019, a novel coronavirus (SARS-CoV-2) pandemic was declared. Social isolation became a mainstay for the prevention of disease expansion. Outpatient follow-up of…
Abstract Number: 0644 • ACR Convergence 2020
Characterizations of Cytokine Storm Associated with COVID19
Ofer Perzon¹, Avi Abutbul¹, Sigal Sviri¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: COVID-19, the name given to the clinical syndrome associated with the newly recognized virus SARS-CoV-2 has become pandemic with mortality estimated based on reports…
Abstract Number: 1416 • ACR Convergence 2020
Effects of the COVID-19 Pandemic on Patients Living with Vasculitis
Shubhasree Banerjee¹, Michael George², Kalen Young³, Shilpa Venkatachalam⁴, Jennifer Gordon⁵, Cristina Burroughs⁶, David Curtis⁷, Marcela Ferrada⁸, Kelly Gavigan⁹, Peter C. Grayson¹⁰, Joyce Kullman¹¹, Jeffrey R Curtis¹², Dianne Shaw³, William Nowell¹³ and Peter Merkel², ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Foundation, Kansas City, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Temple University, Philadelphia, ⁶University of South Florida, Tampa, ⁷Global Healthy Living Foundation, New York City, ⁸Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹Global Healthy Living Foundation, Upper Nyack, NY, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ¹¹Vasculitis Foundation, Kansas City, MO, ¹²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Global Healthy Living Foundation, New York City, NY
Background/Purpose: The COVID-19 pandemic has the potential to impact how patients with vasculitis interact with health care systems due to concerns about infections. This study…
Abstract Number: 1961 • ACR Convergence 2020
Decreased Visits in RISE Practices Due to the SARS-CoV-2 Global Pandemic
Jing Li¹, Sarah Ringold², Jeffrey R Curtis³, Kaleb Michaud⁴, Tracy Johansson⁵, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹University of California, San Francisco, San Francisco, CA, ²Seattle Children's, Seattle, WA, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Adult / ACR Test Training Program #4, Atlanta, GA, ⁶UCSF, San Francisco, CA, ⁷University of California, San Francisco, Atherton, CA
Background/Purpose: The SARS-CoV-2 global pandemic has resulted in major disruptions to medical care, including rheumatology. We aimed to understand the changes in clinical visit counts…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].